Pierre N. Tariot, MD
Professor of Psychiatry, Medicine, Neurology,
and Aging and Developmental Biology
University of Rochester Medical Center
Director of Psychiatry
Monroe Community Hospital
Rochester, New York
Manju T. Beier, PharmD
Clinical Associate Professor of Pharmacy
The University of Michigan
Geriatric Consultant Resources, LLC
Ann Arbor, MI
CREDIT FOR THIS PROGRAM IS AVAILABLE FOR PHARMACISTS ONLY
As the population ages, dementia becomes an increasingly common problem. Although it has several potential etiologies, Alzheimerís disease is by far the most common. However, Lewy body dementia, as well as vascular dementia, should be recognized by healthcare professionals who care for older adults.
Dementia is often associated with behavioral disturbances and psychosis as well as cognitive and functional impairment. Several classes of medication are available to treat the psychotic symptoms associated with the more severe forms of dementia, but each drug class, as well as individual agents within each class, comes with its own efficacy and side-effect profile, which can be affected by the patientís co-morbidity and concomitant drug regimens.
When used appropriately, antipsychotic agents can ameliorate behavioral and psychotic symptoms in patients with dementia, but these drugs are not without risk, particularly in such a vulnerable population. Whether they see older adults in the community or in long-term care settings, healthcare providers need to understand the benefits and risks associated with each antipsychotic drug used in this population.
This program will provide an overview of the data for antipsychotic drugs in older adults with updates from recent studies in patients with Alzheimerís disease, Lewy body dementia, and Parkinsonís disease. Two case studies will also be presented to highlight practical and sometimes difficult treatment considerations.
. Target Audience
Consultant pharmacists and VA pharmacists who treat dementia in older adults.
Upon completion of this educational activity, the participant should be able to:
Describe the benefits and risks associated with atypical antipsychotics in the older adult with dementia
Discuss current studies evaluating the use of atypical antipsychotics in older adults with various dementias
Recognize the presentation of Lewy body dementia and other forms of dementia
Implement treatment strategies to individualize and optimize atypical antipsychotic therapy in older adults
Dr. Tariot has received consultant fees, research support and honoraria from AstraZeneca, Janssen Pharmaceutica Inc., Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Eisai, and Forest Laboratories, Inc.
Dr. Beier has received honoraria and consultant fees from Janssen Pharmaceutica Inc., and Bristol-Myers Squibb, honoraria from AstraZeneca, and consultant fees from Eli Lilly and Company.
The program faculty will discuss off-label, unapproved and/or investigational use of atypical antipsychotic agents in this educational presentation. The atypical antipsychotic agents are approved only for the
treatment of schizophrenia.
This program (#203-999-03-668-H01) was developed by the American Society of Consultant Pharmacists (ASCP) and is approved for 1.0 Contact Hour (0.1 CEU). ASCP is approved by the American Council on Pharmaceutical Education (ACPE) as a provider of continuing pharmaceutical education.
This program was originally presented as a live audioconference series beginning in April 2003. If you participated in the live audioconference (UPN# 203-000-03-668-CO1), or in the subsequent audio-CD/workbook release of the program, you are not eligible to receive continuing education credit through this online program.
Credit will be awarded upon submission of a completed program evaluation and a post-test with a passing grade of 70% or better.
Commercial Support Statements
Supported by an unrestricted educational grant from AstraZeneca.
Click on the "Start program" icon.
The next screen will permit you to check for or download Flash, required to run this program. You will also find buttons which will permit you to start the program presentation, access other program elements, and take the post-test.
Clicking on "start the program" on this screen will begin the program presentation which will take approximately 1 hour to complete.
You must be registered with cmecorner.com in order to complete the post-test. When you click on the post-test button you will be brought to a screen which will confirm your registration status and provide an opportunity to register if you haven't done so previously.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a Statement of Credit.
None of the contents of this program may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this activity are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the American Society of Consultant Pharmacists AKH Consultant, or AstraZeneca. Any medications, or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patientsí conditions and of possible contraindications or risks, and without a review of any applicable manufacturerís product information and comparison with the recommendations of other authorities.